Company: Aquinnah Pharmaceuticals
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease
Mechanism Type: Stress granule clearance
Mechanism: Aquinnah is developing compounds that eliminate TDP-43-positive stress granules which are estimated to persist in more than 75% of cases of the disease.
U.S. Status for ALS: Preclinical
 Aquinnah Pharmaceuticals Receives $5 Million Investment from Takeda Pharmaceuticals To Advance New Therapies in ALS. PR Newswire, 21 Dec 2015. Accessed 28 Dec 2015 from http://www.prnewswire.com/news-releases/aquinnah-pharmaceuticals-receives-5-million-investment-from-takeda-pharmaceuticals-to-advance-new-therapies-in-als-300195607.html.
Last updated December 28th, 2015